A Phase 1 clinical trial of investigational vaccines intended to protect against Zaire ebolavirus (Ebola) has begun in the United States at Cincinnati Children’s Hospital Medical Center. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts. Scientists at Texas Biomedical Research Institute were part of a nationwide collaborative with scientists at Gladstone Institutes, UC San Francisco and Georgia State University for a study recently published in the journal Cell.
Ebola virus (green) infects human cells much more easily when you remove the protective RBBP6 protein (compare left to right). Researchers have discovered a human protein that helps fight the Ebola virus and could one day lead to an effective therapy against the deadly disease, according to a new study from Northwestern University, Georgia State University, University of California, San Francisco (UCSF) and the Gladstone Institutes published today, Dec.
Texas Biomed researchers – in collaboration with the University of Iowa – are trying to find out how malarial infections impact people exposed to Ebola virus. Both diseases are endemic in that region.
A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.
A new study from the NYU College of Global Public Health and NYU Tandon School of Engineering, published in Nature Digital Medicine, used text message surveys to determine in real time how people used maternal health services during a recent Ebola outbreak and measured a drop in hospital-based births during the outbreak.
Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
Geneticist Jason Ladner talks about the study, which underscores the need for focused prevention efforts among survivors and better capacity to detect new cases of the deadly virus.
A new study at Texas Biomedical Research Institute is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication.
A uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found.
WASHINGTON — Georgetown University professors offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include infectious disease control and treatment, vaccine development, clinical trials, global health security, and international health regulations. To schedule an interview, please contact Karen Teber at km463@georgetown.
Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.
New Scripps Research study offers guidance for more effective Ebola vaccines
Protein fragments, called amyloid fibrils, in human semen significantly increase Ebola virus infection and protect the virus against harsh environmental conditions such as heat and dehydration. Follow-up studies from the 2014 epidemic found that men can harbor the virus in their semen for at least 2.5 years, with the potential to transmit the virus sexually during that time. Targeting amyloids in semen may prevent a sexually transmitted spread of the Ebola virus.
Research conducted in vitro shows two human antibodies made in response to vaccination against one hemorrhagic fever virus can disarm a related virus, for which there is currently no vaccine. The proof-of-principle finding identifies a common molecular chink in the two viruses’ armor that renders both vulnerable to the same antibodies. The results set the stage for a single vaccine and other antibody-based treatments that work against multiple viral “cousins” despite key differences in their genetic makeup. Such therapies can alleviate challenges posed by current lack of vaccines and prevent outbreaks of viral hemorrhagic fevers.
The viruses that cause Ebola and Zika, daunting diseases that inspire concern at every outbreak, share a strong similarity in how they first infiltrate a host’s cells.
An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right